|
||||||||||||||||||||||
|
|
Alternate Title Phase III Randomized Study of Selenium in Patients With Adenomatous Colorectal Polyps
Special Category: NCI Web site featured trial Trial Description Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Selenium may be effective in preventing the recurrence of adenomatous colorectal polyps. This randomized phase III trial is studying selenium to see how well it works in preventing the recurrence of polyps in patients with adenomatous colorectal polyps. Eligibility criteria include the following:
Final eligibility for a clinical trial is determined by the health professionals conducting the trial. Patients will be randomly assigned to one of two groups. Patients in group one will receive selenium by mouth once a day. Patients in group two will receive a placebo by mouth once a day. Treatment in both groups may continue for up to 5-7.6 years. Patients will undergo a follow-up colonoscopy periodically for approximately 5-7.6 years after the initial colonoscopy. Important: For more details about this trial, refer to the Health Professional version of the trial summary. If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site. Trial Lead Organizations Arizona Cancer Center at University of Arizona Health Sciences Center
Related Information
|
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |